Currently, tumour PD-1 ligand (PD-L1) expression determined by immunohistochemistry (IHC) is the only accepted predictive biomarker for anti-PD-1 therapy response in clinical practice; however, its prediction accuracy is relatively weak. Here, CD274 is linked to neoplasm.